Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
- Status
- RECRUITING
- Phase
- PHASE3
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
- Status
- RECRUITING
- Phase
- PHASE2
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
- Status
- RECRUITING
- Phase
- PHASE2
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
- Status
- RECRUITING
- Phase
- PHASE2
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE4
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
- Status
- RECRUITING
- Phase
- PHASE2
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
- Status
- RECRUITING
- Phase
- PHASE2
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- N/A
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
- Status
- RECRUITING
- Phase
- PHASE2